Pro­to­cols: Tri­ci­da bags $55M round for CKD drug; $MRK gets a 'break­through’;

South San Fran­cis­co-based Tri­ci­da has brought its to­tal fundrais­ing to $95 mil­lion, with a new $55 mil­lion C round ear­marked to fund its work on an ex­per­i­men­tal ther­a­py for chron­ic kid­ney dis­ease. Com­pa­ny CEO Ger­rit Klaern­er says the biotech is “on track to com­plete a first-in-hu­man 100 pa­tient phase 1/2 study of its lead com­pound, TRC101, in 2016, and is prepar­ing to dis­cuss the safe­ty and ef­fi­ca­cy re­sults from the study with the FDA in a Type B meet­ing lat­er this year.” Lon­gi­tude Cap­i­tal led the round with par­tic­i­pa­tion by new in­vestor Vi­vo Cap­i­tal and ex­ist­ing in­vestors Or­biMed, Sib­ling Cap­i­tal Ven­tures and Limu­lus Ven­ture Part­ners.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.